Enterprise Value
1.152B
Cash
626.3M
Avg Qtr Burn
-79.69M
Short % of Float
11.47%
Insider Ownership
0.37%
Institutional Own.
89.98%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Lifileucel Details Melanoma, Cancer | BLA Acceptance for review | |
LN-145 Details Non-small cell lung carcinoma, Cancer | Phase 2 Data readout | |
LN-145 Details Head and neck cancer, Head and neck squamous cell carcinoma, Cancer | Phase 2 Data readout | |
Lifileucel Details Cancer, Ovarian cancer | Phase 2 Data readout | |
IOV-4001 Details Non-small cell lung carcinoma, Cancer, Melanoma | Phase 1/2 Data readout |